Chemed Co. (NYSE:CHE) saw a significant increase in short interest in November. As of November 29th, there was short interest totalling 257,700 shares, an increase of 6.5% from the November 14th total of 242,000 shares. Based on an average daily volume of 98,500 shares, the days-to-cover ratio is presently 2.6 days. Approximately 1.7% of the company’s shares are short sold.
CHE traded up $3.75 during trading on Friday, hitting $440.12. The company had a trading volume of 70,333 shares, compared to its average volume of 87,222. The company has a market capitalization of $6.97 billion, a PE ratio of 36.89, a PEG ratio of 2.98 and a beta of 1.11. Chemed has a one year low of $260.03 and a one year high of $441.79. The firm’s 50-day moving average price is $419.06 and its 200 day moving average price is $400.16. The company has a quick ratio of 0.64, a current ratio of 0.67 and a debt-to-equity ratio of 0.32.
Chemed (NYSE:CHE) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $3.46 EPS for the quarter, beating the consensus estimate of $3.31 by $0.15. The business had revenue of $480.61 million for the quarter, compared to analysts’ expectations of $478.89 million. Chemed had a net margin of 11.14% and a return on equity of 35.06%. The firm’s revenue was up 8.2% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.07 EPS. Sell-side analysts forecast that Chemed will post 13.47 earnings per share for the current year.
CHE has been the topic of several research reports. JMP Securities raised shares of Chemed from a “market perform” rating to an “outperform” rating and set a $490.00 price objective on the stock in a research report on Friday, November 1st. ValuEngine cut shares of Chemed from a “hold” rating to a “sell” rating in a research report on Tuesday, December 3rd. Bank of America boosted their price objective on shares of Chemed from $470.00 to $500.00 and gave the company a “buy” rating in a research report on Friday, September 6th. Finally, Oppenheimer boosted their price objective on shares of Chemed from $440.00 to $470.00 and gave the company a “market perform” rating in a research report on Monday, November 25th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $435.00.
In other news, Director Frank E. Wood sold 5,451 shares of Chemed stock in a transaction on Wednesday, September 25th. The shares were sold at an average price of $419.62, for a total transaction of $2,287,348.62. Following the transaction, the director now directly owns 5,429 shares of the company’s stock, valued at $2,278,116.98. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Frank E. Wood sold 2,772 shares of Chemed stock in a transaction on Monday, October 14th. The stock was sold at an average price of $414.75, for a total transaction of $1,149,687.00. Following the transaction, the director now directly owns 5,429 shares in the company, valued at $2,251,677.75. The disclosure for this sale can be found here. Over the last three months, insiders have sold 15,683 shares of company stock worth $6,582,111. Insiders own 3.96% of the company’s stock.
A number of large investors have recently modified their holdings of the business. BlackRock Inc. lifted its position in Chemed by 2.5% during the 2nd quarter. BlackRock Inc. now owns 1,697,275 shares of the company’s stock worth $612,445,000 after buying an additional 42,102 shares in the last quarter. Invesco Ltd. lifted its position in Chemed by 7.4% during the 2nd quarter. Invesco Ltd. now owns 262,075 shares of the company’s stock worth $94,567,000 after buying an additional 18,100 shares in the last quarter. TimesSquare Capital Management LLC lifted its position in Chemed by 27.9% during the 2nd quarter. TimesSquare Capital Management LLC now owns 217,000 shares of the company’s stock worth $78,302,000 after buying an additional 47,300 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Chemed by 4.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 201,475 shares of the company’s stock worth $72,700,000 after buying an additional 8,586 shares in the last quarter. Finally, Voya Investment Management LLC lifted its position in Chemed by 9.0% during the 3rd quarter. Voya Investment Management LLC now owns 187,632 shares of the company’s stock worth $78,349,000 after buying an additional 15,429 shares in the last quarter. 88.84% of the stock is currently owned by hedge funds and other institutional investors.
Chemed Corporation provides hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers in the United States. It operates through two segments, VITAS and Roto-Rooter. The company also offers plumbing, drain cleaning, water restoration, and other related services to residential and commercial customers through company-owned and independent contractors, and franchised locations.
See Also: What is a stock split?
Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.